Form 4 holding
10%+ Owner
Entrada Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 2,813,525
- Estimated value
- $44,988,265
- Report date
- 02 Nov 2021
- Price
- $15.99
- Ownership
- Indirect
ROCHE HOLDING LTD
Insider Reports History
- Reporting-owner location
- Basel
- Latest reporting-owner signature
-
ROCHE FINANCE LTD, By: /s/ Peter Trybus, Authorized Signatory
Source: Latest parsed Forms 3/4/5 signature
- Transaction source note
- Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.
Identity
Names, identifiers, and filing context for this profile.
1 identity field
SEC source record
Original filing metadata and source links for verification.
1 source field
Source evidence
Original filing metadata and source links for verification.
1 source field
Reported holdings for ROCHE HOLDING LTD
Form 4 holding
10%+ Owner
Jasper Therapeutics, Inc.
- Security class
- Voting Common Stock
- Shares / value
- 4,549,606
- Estimated value
- $2,950,874
- Report date
- 25 Jan 2023
- Price
- $0.6486
- Ownership
- Indirect
Form 4 holding
10%+ Owner
Aligos Therapeutics, Inc.
- Security class
- Common Stock, par value $0.0001 per share
- Shares / value
- 11,025,941
- Estimated value
- Report date
- 25 Oct 2023
- Price
- Ownership
- Indirect
Form 4 holding
10%+ Owner
Entrada Therapeutics, Inc.
- Security class
- Series A Preferred Stock
- Shares / value
- 0
- Estimated value
- Report date
- 02 Nov 2021
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
10%+ Owner
Entrada Therapeutics, Inc.
- Security class
- Series B Preferred Stock
- Shares / value
- 0
- Estimated value
- Report date
- 02 Nov 2021
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Insider Reports Filed by ROCHE HOLDING LTD
3
ALGS
Aligos Therapeutics, Inc.
- Report period
- 25 Oct 2023
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 07 Nov 2023, 17:14
- Role
- 10%+ Owner
- Next action
- Open filing details
4
JSPR
Jasper Therapeutics, Inc.
- Report period
- 25 Jan 2023
- Transactions
- 1
- Transaction value
- -$141,750
- Accepted by SEC
- 26 Jan 2023, 16:49
- Role
- 10%+ Owner
- Next action
- Open filing details
4
TRDA
Entrada Therapeutics, Inc.
- Report period
- 02 Nov 2021
- Transactions
- 4
- Transaction value
- $0
- Accepted by SEC
- 04 Nov 2021, 21:45
- Role
- 10%+ Owner
- Next action
- Open filing details
3
TRDA
Entrada Therapeutics, Inc.
- Report period
- 28 Oct 2021
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 28 Oct 2021, 21:04
- Role
- 10%+ Owner
- Next action
- Open filing details
3
JSPR
Jasper Therapeutics, Inc.
- Report period
- 24 Sep 2021
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 04 Oct 2021, 09:10
- Role
- 10%+ Owner
- Next action
- Open filing details